Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 26-Jan-24 4:07 PM View:  | Hecht Peter M Director 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 01-Jan-24 | Grant | 15,000 | -- | -- | 4% 362.46K to 377.46K | |
| 26-Jan-24 4:05 PM View: | Graul Regina Margaret President | Cyclerion Therapeutics, Inc. (CYCN) | 01-Jan-24 | Grant | 50,000 | -- | -- | 99% 50.3K to 100.3K | |
| 04-Dec-23 4:05 PM View: | Hecht Peter M Director 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 01-Dec-23 | Grant | 15,000 | -- | -- | 4% 347.46K to 362.46K | |
| 04-Dec-23 4:05 PM View: | McGuire Terrance Director | Cyclerion Therapeutics, Inc. (CYCN) | 30-Nov-23 | Grant | 5,000 | -- | -- | 14% 37.01K to 42.01K | |
| 04-Dec-23 4:05 PM View: | Hecht Peter M Director 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 30-Nov-23 | Grant | 20,000 | -- | -- | 6% 327.46K to 347.46K | |
| 04-Dec-23 4:04 PM View: | Hyman Steven Director | Cyclerion Therapeutics, Inc. (CYCN) | 30-Nov-23 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 11-Aug-23 4:25 PM View: | McGuire Terrance Director | Cyclerion Therapeutics, Inc. (CYCN) | 09-Aug-23 | Private Sale | 8 | $3.39 | $27.16 | (< 1%) 37.02K to 37.01K | |
| 22-May-23 8:43 PM View: | Hecht Peter M Chief Executive Officer Director 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 19-May-23 | Grant | 225,000 | $8.68 | $1,953,000.00 | 220% 102.46K to 327.46K | |
| 07-Jun-21 4:05 PM View: | Slate Path Capital Lp 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 03-Jun-21 | Market Purchase | 961,538 | $3.12 | $3,000,000.00 | 16% 6.2M to 7.16M | 2% |
| 07-Jun-21 5:25 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 03-Jun-21 | Market Purchase | 823,170 | $3.28 | $2,700,000.00 | 67% 1.23M to 2.05M | (3%) |
| 07-Jun-21 5:36 PM View: | McGuire Terrance Director | Cyclerion Therapeutics, Inc. (CYCN) | 03-Jun-21 | Market Purchase | 96,153 | $3.12 | $299,997.00 | 15% 644.24K to 740.39K | 2% |
| 10-May-21 8:45 AM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 06-May-21 | Market Purchase | 302,000 | $2.43 | $733,860.00 | 33% 923.98K to 1.23M | 14% |
| 06-May-21 9:27 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 05-May-21 | Market Purchase | 398,001 | $2.53 | $1,006,940.00 | 76% 525.98K to 923.98K | < 1% |
| 06-May-21 9:27 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 04-May-21 | Market Purchase | 300,000 | $2.29 | $687,000.00 | 133% 225.98K to 525.98K | 11% |
| 01-Mar-21 4:23 PM View: | Gjino Anjeza Chief Financial Officer | Cyclerion Therapeutics, Inc. (CYCN) | 25-Feb-21 | Market Sale (Planned) | 1,824 | $4.00 | $7,296.00 | (5%) 33.42K to 31.6K | |
| 01-Mar-21 4:17 PM View: | Wright Christopher I Chief Medical Officer | Cyclerion Therapeutics, Inc. (CYCN) | 25-Feb-21 | Market Sale (Planned) | 2,637 | $3.99 | $10,521.60 | (6%) 45.37K to 42.73K | |
| 30-Dec-20 1:14 PM View: | Currie Mark G President and CSO | Cyclerion Therapeutics, Inc. (CYCN) | 28-Dec-20 | Market Sale | 20,107 | $3.01 | $60,522.10 | (7%) 271.75K to 251.65K | < 1% |
| 12-Nov-20 5:05 PM View: | Busch Andreas Chief Innovation Officer | Cyclerion Therapeutics, Inc. (CYCN) | 09-Nov-20 | Market Purchase | 125,000 | $2.53 | $316,250.00 | 96% 129.7K to 254.7K | 26% |
| 10-Nov-20 7:07 PM View: | Huyett William Chief Financial Officer | Cyclerion Therapeutics, Inc. (CYCN) | 06-Nov-20 | Market Sale (Planned) | 3,827 | $2.52 | $9,644.04 | (5%) 71.42K to 67.59K | (26%) |
| 25-Feb-20 4:11 PM View: | Huyett William Chief Financial Officer | Cyclerion Therapeutics, Inc. (CYCN) | 21-Feb-20 | Market Sale (Planned) | 3,559 | $5.12 | $18,222.10 | (5%) 74.98K to 71.42K | 38% |
| 31-Dec-19 5:55 PM View: | Currie Mark G President | Cyclerion Therapeutics, Inc. (CYCN) | 30-Dec-19 | Market Sale | 25,000 | $2.48 | $62,000.00 | (8%) 296.75K to 271.75K | (29%) |
| 31-Dec-19 5:55 PM View: | Currie Mark G President | Cyclerion Therapeutics, Inc. (CYCN) | 27-Dec-19 | Market Sale | 25,000 | $2.55 | $63,750.00 | (8%) 321.75K to 296.75K | (25%) |
| 19-Nov-19 4:02 PM View: | Busch Andreas Chief Innovation Officer | Cyclerion Therapeutics, Inc. (CYCN) | 15-Nov-19 | Market Purchase | 125,000 | $1.82 | $227,500.00 | 100% 0 to 125.0K | 75% |
| 12-Nov-19 4:26 PM View: | Huyett William Chief Financial Officer | Cyclerion Therapeutics, Inc. (CYCN) | 08-Nov-19 | Market Sale (Planned) | 3,922 | $2.05 | $8,040.10 | (5%) 78.9K to 74.98K | (56%) |
| 12-Jul-19 4:09 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 10-Jul-19 | Option Exercise | 2,000 | $6.04 | $12,080.00 | < 1% 224.65K to 226.65K | |
| 10-Apr-19 4:14 PM View: | McGuire Terrance Director | Cyclerion Therapeutics, Inc. (CYCN) | 08-Apr-19 | Market Purchase Duplicate | 626,117 | $16.00 | $10,017,900.00 | 3455% 18.12K to 644.24K | (80%) |
| 10-Apr-19 4:13 PM View: | Schulman Amy W Director | Cyclerion Therapeutics, Inc. (CYCN) | 08-Apr-19 | Market Purchase | 626,117 | $16.00 | $10,017,900.00 | 8339% 7.51K to 633.63K | (80%) |
| 03-Apr-19 7:42 PM View: | Currie Mark G President | Cyclerion Therapeutics, Inc. (CYCN) | 02-Apr-19 | Purchase | 270,107 | $14.81 | $4,000,280.00 | 523% 51.65K to 321.75K | |
| 03-Apr-19 7:39 PM View: | Huyett William Chief Financial Officer | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 77,506 | -- | -- | 5513% 1.41K to 78.91K | |
| 03-Apr-19 8:30 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 1,455 | -- | -- | < 1% 223.19K to 224.65K | |
| 03-Apr-19 9:14 PM View: | McGuire Terrance Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 7,073 | -- | -- | 216% 3.28K to 10.35K | |
| 03-Apr-19 7:32 PM View: | Fanucci Marsha Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 16,950 | -- | -- | 100% 0 to 16.95K | |
| 03-Apr-19 7:17 PM View: | Isacson Ole Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 2,421 | -- | -- | 100% 0 to 2.42K | |
| 03-Apr-19 7:34 PM View: | Schulman Amy W Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 7,508 | -- | -- | 100% 0 to 7.51K | |
| 03-Apr-19 7:42 PM View: | Currie Mark G President | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 51,648 | -- | -- | 100% 0 to 51.65K | |
| 03-Apr-19 5:43 PM View: | Churchwell Kevin Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 2,421 | -- | -- | 100% 0 to 2.42K | |
| 03-Apr-19 7:21 PM View: | Lovell Stephanie Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 2,421 | -- | -- | 100% 0 to 2.42K | |
| 03-Apr-19 8:30 PM View: | Hecht Peter M Chief Executive Officer Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 223,192 | -- | -- | 100% 0 to 223.19K | |
| 02-Apr-19 9:39 PM View: | Ironwood Pharmaceuticals Inc 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Disposition (other) | 15,562,600 | -- | -- | (100%) 15.56M to 0 | |
| 03-Apr-19 6:44 PM View: | Conrades George N Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 2,421 | -- | -- | 100% 0 to 2.42K | |
| 03-Apr-19 7:23 PM View: | Mendelsohn Michael Director | Cyclerion Therapeutics, Inc. (CYCN) | 01-Apr-19 | Grant | 2,421 | -- | -- | 100% 0 to 2.42K | |
| 02-Apr-19 9:39 PM View: | Ironwood Pharmaceuticals Inc 10% Owner | Cyclerion Therapeutics, Inc. (CYCN) | 29-Mar-19 | Grant | 15,562,500 | -- | -- | 15562500% 100 to 15.56M |
